メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
富山大学 ホーム
日本語
English
ホーム
プロファイル
研究部門
プロジェクト
研究成果
データセット
受賞
活動
コース
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
元尾 伊織
助教, 博士（医学） 富山大学 2019年9月
内科学（第三）講座
h-index
1635
被引用数
6
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2017
2024
年別の研究成果
概要
フィンガープリント
ネットワーク
プロジェクト
(1)
研究成果
(13)
データセット
(2)
コース
(1)
類似のプロファイル
(6)
フィンガープリント
Iori Motooが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Keyphrases
19-gauge
28%
Advanced Gastric Cancer
80%
Anticancer Immunity
28%
Biopsy Needle
28%
CD8+ T Cells
31%
Chemotherapy-induced Diarrhea
28%
Colorectal Cancer
42%
Commensal
28%
Constitutional Mismatch Repair Deficiency (CMMRD)
28%
Deficiency Cases
28%
Diarrhea
28%
Differential Diagnosis
34%
Duodenal Stenosis
28%
Ectopic Colonization
28%
Endoscopic Ultrasound
28%
Endoscopic Ultrasound Guided Biopsy
28%
Endoscopic Ultrasound-guided Fine-needle Aspiration (EUS-FNA)
76%
Epithelial-mesenchymal Transition
28%
Fine-needle Aspiration Biopsy
28%
Fluoropyrimidine
28%
Franseen Needle
57%
Gastric Cancer
59%
Gastrointestinal Cancer
34%
Gastrointestinal Tumours
28%
Hepatic Angiomyolipoma
28%
Hepatocellular Carcinoma
28%
Histological Samples
28%
Immune Checkpoint Inhibitors
31%
Immune-related Adverse Events
28%
Inflammation
42%
Intensive Surveillance
28%
Intestinal mucosal Injury
28%
Intestine
42%
Klebsiella
28%
Methylation
29%
Nivolumab
42%
Oral Bacteria
28%
Pathological Diagnosis
42%
Pembrolizumab
28%
Poor Differentiation
28%
Portal Phase
28%
Retrospective Analysis
28%
Risk Factors
31%
Solid Pancreatic Lesions
28%
Surveillance Colonoscopy
28%
T Helper 1
28%
Tumor
23%
ULK2
28%
Ultrasound Examination
28%
Urothelial Carcinoma
28%
Medicine and Dentistry
Abdominal Cancer
71%
Angiomyolipoma
28%
Binimetinib
14%
Biological Marker
14%
Biopsy Technique
42%
Blood Clot
14%
Carbohydrate Antigen
14%
Colectomy
16%
Colorectal Carcinoma
22%
Constipation
14%
Diagnosis
35%
Diagnostic Accuracy
11%
Differential Diagnosis
32%
DNA Mismatch Repair
28%
Duodenum
14%
Duodenum Stenosis
28%
Endoscopic Ultrasound
57%
Endoscopic Ultrasound Guided Fine Needle Biopsy
79%
Endoscopy
28%
Esophagogastroduodenoscopy
11%
Exudative Retinal Detachment
14%
Fine-Needle Aspiration
57%
Gastrointestinal Tumor
28%
Hepatocellular Carcinoma
28%
Hydronephrosis
14%
Immune Checkpoint Inhibitor
17%
Immune-Related Adverse Events
30%
Linitis Plastica
14%
Liver Metastasis
14%
Liver Tumor
19%
Magnetic Resonance Imaging
28%
MEK Inhibitor
14%
Metastatic Carcinoma
12%
Monotherapy
14%
N [bis(1 Aziridinyl)phosphinyl] 4 Iodobenzamide
28%
Neoplasm
39%
Nivolumab
42%
Overall Survival
17%
Pancreas Cancer
19%
Patient Characteristics
14%
Pembrolizumab
28%
Pentetic Acid
19%
Peritoneum Metastasis
28%
Polyp
12%
Progression Free Survival
13%
Ramucirumab
14%
Retinal Detachment
9%
Tail
14%
Transitional Cell Carcinoma
28%
TRPV4
14%
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Cancer
100%
Adverse Event
42%
Ascites
7%
Binimetinib
10%
Biological Marker
14%
Butyrate
5%
Carbohydrate Antigen
14%
Chemotherapy
46%
Clinical Trial
14%
Colorectal Carcinoma
14%
Combination Therapy
21%
Constipation
21%
Diarrhea
35%
Digestive System Cancer
28%
Diseases
14%
Disseminated Intravascular Clotting
14%
Dysbiosis
7%
Dysphagia
14%
Escherichia coli
11%
Esophagus Cancer
14%
Fluoropyrimidine
28%
Folic Acid
5%
Immune Checkpoint Inhibitor
31%
Injury
28%
Intestine Flora
5%
Irritable Colon
14%
Liver Metastasis
14%
Microflora
5%
Mitogen Activated Protein Kinase Kinase Inhibitor
14%
Monotherapy
14%
Nivolumab
50%
Normal Human
14%
Overall Survival
27%
Pembrolizumab
30%
Peritoneum Metastasis
28%
Primary Tumor
7%
Progression Free Survival
19%
Prospective Study
7%
Ramucirumab
16%
Retina Detachment
14%
Retrospective Study
5%
Taxane
14%
Tumor Necrosis Factor
14%
